Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy

Cisplatin, a widely used chemotherapeutic agent, induces a sensory neuropathy with selective loss of vibration sense and proprioception. Here we demonstrate that neurotrophin‐3 (NT‐3), a member of the nerve growth factor family of neurotrophic factors, restored to normal levels the reduced H‐reflex‐related sensory nerve conduction velocity induced by cisplatin in rats. NT‐3 treatment corrected an abnormal cytoplasmic distribution of neurofilament protein in large sensory neurons in dorsal root ganglia and the reduction in the numbers of myelinated fibers in sural nerves caused by cisplatin. The NT‐3–dependent reversal of cisplatin neurotoxicity thus suggests the possible use of NT‐3 in the treatment of peripheral sensory neuropathy.

[1]  W. Snider,et al.  Functions of the neurotrophins during nervous system development: What the knockouts are teaching us , 1994, Cell.

[2]  S. McMahon,et al.  Expression and coexpression of Trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets , 1994, Neuron.

[3]  Yves-Alain Barde,et al.  Neurotrophin-3 enhances sprouting of corticospinal tract during development and after adult spinal cord lesion , 1994, Nature.

[4]  M. Jacquin,et al.  NGF Augmentation rescues trigeminal ganglion and principalis neurons, but not brainstem or cortical whisker patterns, after infraorbital nerve injury at birth , 1993, The Journal of comparative neurology.

[5]  I. Silos-Santiago,et al.  Neurotrophin receptor genes are expressed in distinct patterns in developing dorsal root ganglia , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  S. Korsching,et al.  The neurotrophic factor concept: a reexamination , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  L. Cork,et al.  Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease , 1993, Cell.

[8]  E. Frank,et al.  Neurotrophin 3 supports the survival of developing muscle sensory neurons in culture. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Stephen R. Rapp,et al.  Nerve Growth Factor Facilitates Regeneration across Nerve Gaps: Morphological and Behavioral Studies in Rat Sciatic Nerve , 1993, Experimental Neurology.

[10]  F. Hefti,et al.  Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  G. Wieneke,et al.  Hypoxic neuropathy versus diabetic neuropathy An electrophysiological study in rats , 1992, Journal of the Neurological Sciences.

[12]  S. Mühlhausen,et al.  Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro. , 1992, Chemico-biological interactions.

[13]  J. Arezzo,et al.  Nerve growth factor prevents experimental cisplatin neuropathy , 1992, Annals of neurology.

[14]  J. Arezzo,et al.  Nerve growth factor prevents toxic neuropathy in mice , 1991, Annals of neurology.

[15]  E. Roubos,et al.  Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. , 1990, Cancer research.

[16]  J. Nagy,et al.  Analysis of parvalbumin and calbindin D28k-immunoreactive neurons in dorsal root ganglia of rat in relation to their cytochrome oxidase and carbonic anhydrase content , 1989, Neuroscience.

[17]  Mark J. Brown,et al.  Dose‐dependent expression of neuronopathy after experimental pyridoxine intoxication , 1989, Neurology.

[18]  A. Hart,et al.  Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. , 1988, Cancer research.

[19]  W. Gispen,et al.  Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. , 1988, European journal of cancer & clinical oncology.

[20]  W. Gispen,et al.  Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. , 1987, Toxicology and applied pharmacology.

[21]  J W Griffin,et al.  Neurofilament gene expression: a major determinant of axonal caliber. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  F. Hefti,et al.  Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  P. Lohman,et al.  Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). , 1985, Cancer research.

[24]  D. Price,et al.  Slow axonal transport in acrylamide neuropathy: different abnormalities produced by single-dose and continuous administration , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[26]  A. Hirano,et al.  Fine Structural Observations of Neurofilamentous Changes in Amyotrophic Lateral Sclerosis , 1984, Journal of neuropathology and experimental neurology.

[27]  T. J. Walsh,et al.  Neurotoxic effects of cisplatin therapy. , 1982, Archives of neurology.

[28]  E. F. Stanley Sensory and motor nerve conduction velocities and the latency of the H reflex during growth of the rat , 1981, Experimental Neurology.

[29]  J. Whitehouse,et al.  Cis-platinum: a new anticancer agent. , 1979, British medical journal.